AEterna Zentaris (NASDAQ:AEZS) reported quarterly losses of $(0.70) per share. This is a 180 percent decrease over losses of $(0.25) per share from the same period last year.
Jury Rules In Favor If Natera, Finding All Asserted Patents Valid And Infringed By ArcherDX/Invitae; Awards $19.35M In Past Damages For Royalties And Lost Profits
Natera has a broad, global IP portfolio of more than 360 issued or pending patents, with more than 180 in the field of oncology/MRD
Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA testing, today
